ASIC loses big as Federal Court clears Wal King and Terracom directors of misleading market
Handing down his decision on Friday, Justice Ian Jackman criticised parts of the civil case argued by the Australian Securities and Investments Commission as 'plainly untenable' and 'unworthy'.
The ASIC lawsuit alleged Mr King, the listed Terracom's former chair, former director Craig Ransley, former chief financial officer Nathan Boom and current chief executive Danny McCarthy misled the market over a whistleblower's claim the listed company was rigging the quality of its coal to get better prices from its customers.
However, in clearing the men, Justice Jackman said ASIC 'should have known' that most of the charges 'had no realistic chance of success, except perhaps in relation to some minor aspects'.
The regulator claimed that the quartet misled investors by approving public and ASX statements in early 2020 that said the listed Terracom had been 'exonerated' of whistleblower Justin William's allegations that quality certificates on thermal coal produced by the Blair Athol mine in Queensland had been manipulated.
ASIC also alleged the men failed to act with the requisite degree of care and diligence in the discharge of their duties as directors and officers of the company.
It said on Friday it would review Justice Jackman's decision before deciding on an appeal.
Mr King was one of Australia's highest-profile chief executives as head of Leighton Holdings, running the construction giant for 23 years before retiring in 2010.
ASIC's case included the claim that he was obliged as a director to read a PwC report commissioned by Terracom's lawyers Ashurst that found quality 'inconsistencies' in 12 of 14 coal shipments tested.
Terracom's testing partner, ALS, separately disclosed in February 2020 after Mr Williams' claims that it found some quality certificates had been changed 'without justification'.
However, Justice Jackman rejected ASIC's arguments about Mr King, saying 'none of the other directors or executives ever suggested to Mr King that the PwC report required consideration or raised concerns'.
'On 27 February 2020, Mr King attended a meeting with TerraCom's auditors (EY), who then had a separate meeting with Ashurst for 1½ hours for the purpose of going through the PwC report, before returning and confirming that EY had no issue with the PwC report and would provide a clean half-yearly report the following day, which is what occurred,' Justice Jackman said.
He also described as 'one of the more extraordinary features of ASIC's case' its contention that Mr McCarthy and Mr Boom should themselves have investigated Mr Williams' allegations, 'despite the fact that Mr McCarthy and Mr Boom were the subject of the allegations made by Mr Williams which were investigated by PwC'.
'They were plainly in a position of conflict, with a real and sensible personal interest in the investigation or inquiries,' he said.
'The position taken by ASIC is plainly untenable.'
A separate ASIC whistleblower victimisation case against Terracom is still in court.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
36 minutes ago
- News.com.au
ASX biotechs join global race for cell therapy breakthroughs
ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to 'break new ground' in treatment of solid tumours with CAR-T and NK cell assets Cell therapies represent a promising frontier in modern medicine, offering potential to treat, and in some cases cure diseases previously considered untreatable. By using living cells, either from the patient (autologous) or a donor (allogeneic), cell therapies aim to repair, replace, or enhance biological functions within the body. Originally pioneered for blood cancers through technologies like chimeric antigen receptor (CAR) T-cell therapies, the field is rapidly expanding into solid tumours, autoimmune conditions, and neurological diseases. Australia has close ties to CAR T-cell therapy development. Melbourne-based Cell Therapies Pty Ltd, the country's largest Therapeutic Goods Administration (TGA) licensed cell and gene therapy manufacturer, was the commercial production partner for Novartis's Kymriah – the first CAR T-cell therapy approved by the US Food and Drug Administration (FDA) in 2017. While the science remains complex, advances in manufacturing, engineering, and clinical design are making next-generation cell therapies more accessible and scalable, positioning them as a key pillar of future healthcare. Several ASX biotechs are positioning themselves at the forefront of cell therapies to capture a share of the global market, which accounted for ~US$6.04 billion in 2024 and is anticipated to close in on US$48bn by 2034, growing at a CAGR of almost 23%. In particular focus here is the treatment of solid tumours, which account for 90% of all cancers but have so far proven difficult to treat with cell therapies. Arovella in rare biotech club targeting CAR-iNKT therapies Arovella Therapeutics (ASX:ALA) is the only ASX-listed biotech delving into CAR Invariant Natural Killer T-cells (iNKT) therapies, and one of only a few globally. CEO Dr Michael Baker told Stockhead iNKT cells were distinct from the more familiar natural killer, or NK cells, which along with T-cells had limitations. T-cells can't be used off-the-shelf unless they are genetically engineered. While NK cells can quickly eliminate abnormal cells such as tumour cells, iNKT cells go further. Not only do they kill like T and NK cells, but they also trigger a longer-lasting response by activating other key parts of the immune system. Because iNKT cells recognise foreign threats differently – unlike classic CAR-T cells – it has been shown in clinical trials that iNKT cells do not cause complications like graft-versus-host disease (GvHD) when administered from a healthy donor to a patient. The FDA has approved seven CAR-T therapies to date, all for blood cancers, but no iNKT treatments. While over 120 global trials are investigating CAR-NK therapies for blood and solid tumours, CAR iNKT research remains limited. Baker said most cell therapies use the patient's own cells (autologous), but this was costly, slow, and relies on compromised cells. Arovella is taking an allogeneic approach, using healthy donor cells to create off-the-shelf, frozen doses shipped to clinics as needed in a 'ready-to-use' model. Its lead therapeutic ALA-101 combines iNKT cells with a CAR that targets CD19, a protein commonly found on B-cell blood cancers like lymphoma and leukaemia. One of Arovella's next key milestones is to apply to the FDA for its first-in-human trial, enrolling non-Hodgkin's lymphoma and leukaemia patients. The company's other key goal is also tackling solid tumours. "The first approved blood cancer targeting CAR-T products have demonstrated just how important cell therapies will be for cancer treatment," Baker said. "We look forward to using our CAR-iNKT cell platform to expand upon that work and aim to create products capable of increasing access and reducing costs. "There is a lot of great science that will continue to advance the off-the-shelf cell therapy sector. "That is why we continue to scour the globe for new IP to build into our CAR-iNKT platform, to either strengthen our CAR-iNKT cells or to broaden the cancer types that we can target.' Imugene also aims to crack solid tumours Imugene (ASX:IMU) is developing cell-based immunotherapies, including allogeneic CAR T-cell therapies, oncolytic viruses and B-cell vaccines, to address both blood cancers and solid tumours. The company's lead cell therapy candidate azercabtagene zapreleucel (azer-cel) is an off-the-shelf CAR T-cell therapy targeting CD19, a protein commonly expressed on malignant B-cells. There are no allogeneic (off the shelf) CAR T therapies approved to date. Azer-cel is currently undergoing clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a hard-to-treat form of non-Hodgkin's lymphoma. In early-phase studies, azer-cel has demonstrated promising results, including high complete response rates and durable remissions in patients who have previously relapsed after autologous CAR T-cell therapies. "We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for lymphoma patients who have failed on several previous therapies including auto CAR T," CEO and managing director Leslie Chong told Stockhead. Imugene's next-generation cell therapy platform OnCARlytics is designed to help overcome one of the biggest challenges in cancer treatment, making solid tumours visible to the immune system. The approach combines Imugene's proprietary CF33 oncolytic virus, which selectively infects and destroys cancer cells, with CD19-targeting CAR T-cells. The CF33 infects tumour cells and forces them to express CD19, a marker typically found on blood cancer cells but absent on solid tumours. By introducing CD19 into the tumour environment, the therapy effectively tags the cancer, allowing CD19-specific CAR T-cells to recognise and attack the tumour. Imugene's pipeline also includes multiple immunotherapy B-cell vaccine candidates, which involve inducing the body to produce polyclonal antibodies against specific tumour-associated antigens. The company's PD1-Vaxx is designed to generate antibodies that block the PD-1 receptor, potentially mimicking the effects of checkpoint inhibitors such as pembrolizumab (Keytruda). The company recently announced the first patient had been dosed in Australia as part of an investigator-sponsored Phase II Neo-POLEM clinical trial, which is evaluating PD1-Vaxx's potential to improve treatment outcomes for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-high) colorectal cancer. This aggressive cancer subtype accounts for ~15% of all colorectal cancer cases. Chimeric advances cell therapy assets in solid tumours Chimeric Therapeutics (ASX:CHM) has three CAR T and NK cell assets in clinical trials. It has an ongoing phase 1/2 clinical trial for its novel CHM CDH17 CAR T-cell therapy targeting advanced colorectal cancer and Neuroendocrine tumours of the midgut. Their second program CHM CLTX CAR T is in a phase 1B clinical trial in recurrent/progressive glioblastoma, a form of brain cancer. CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial, demonstrated safety and efficacy in blood cancers and solid tumours. Two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated in Acute Myeloid Leukemia (AML). "We're excited to be actively advancing in the clinic and pushing through dose levels as we break new ground in the solid tumour CAR T-cell therapy space," CEO Dr Rebecca McQualter told Stockhead. Prescient advancing cell therapy platforms While predominately focused on PTX-100, its first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1), Prescient Therapeutics (ASX:PTX) is also advancing its proprietary OmniCAR and CellPryme platforms. OmniCar has potential to allow CAR T therapy cells to be more targeted, safer, more effective, cost-effective and of longer duration. CellPryme is a complementary application to OmniCar split into two components. CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. Meanwhile, CellPryme-A acts as an adjuvant therapy, increasing the expansion of CAR T-cells and enhancing their ability to penetrate the tumour. AdAlta adopts East to West cellular immunotherapy strategy AdAlta (ASX:1AD) and venture capital firm SYNthesis BioVentures Fund (SYNBV) launched AdCella in 2024 to adopt an East to West strategy and bring cutting-edge cellular immunotherapies from Asia, particularly China, into Western markets. SYNBV was co-founded by Professor Andrew Wilks, who alongside Amplia (ASX:ATX) CEO Dr Chris Burns received the 2024 Prime Minister's Prize for Innovation for co-inventing momelotinib, an FDA-approved treatment for myelofibrosis. The strategy leverages AdAlta managing director and CEO Dr Tim Oldham's deep expertise in cellular immunotherapies and extensive operational experience in Asia to identify and advance promising Asian cellular therapies that can be transitioned into regulated western markets. Oldham was previously CEO of Cell Therapies and said he'd been fortunate to witness firsthand the rapid evolution of China's biotech sector and remarkable progress in cellular immunotherapies for cancer treatment over the past 15 years. The East to West cellular immunotherapy strategy for cancer is now a core growth priority for AdAlta and a key driver of future pipeline growth and value creation.
Courier-Mail
an hour ago
- Courier-Mail
Airport richlister pays $17m for beachfront holiday pad
An airport magnate has paid nearly $17m for a first-class seat in one of Australia's hottest beachfront markets. The owner of Australia's only privately funded airport, John Wagner, has been revealed as the buyer of a luxe holiday home in the 'Billionaire's Row' of the Gold Coast, as beachfront property prices continue to take off. Records show the Queensland businessman has forked out $16.75m for the four-level, six-bedroom house in Hedges Ave house, Mermaid Beach. RELATED: Glitter Strip developer sells family mansion in beachfront deal That's almost double what the vendor, Azzura Group boss Roberto Badalotti, purchased the property for in 2007. Kollosche principal Michael Kollosche and agent Harry Kakavas sealed the sale of the Hedges Ave pad, described in the listing as 'the pinnacle of luxury'. Mr Kakavas would not disclose the buyer's identity at the time of sale, but confirmed the property was purchased by 'an extremely well-known family' as a holiday home. MORE: Banks quash interest rate frenzy Culture Kings founders' bold $30m push Records now show that family was none other than the Wagner family family behind the Toowoomba Wellcamp Airport, west of Brisbane. The Wagner family is worth about $1.1 billion and its latest foray in Toowoomba is a sustainable fuels business joint venture that plans to develop a facility to turn waste-based feedstocks into sustainable aviation fuel. The fuel could be used for flights in and out of Wellcamp. The airport and surrounding land including a business park, trade, aerospace and defence zones, form the basis of the Wagners' wealth, along with the ASX-listed Wagner Holding Co building materials company. 'The beachfront is going from strength to strength because of the limited supply,' Mr Kakavas told News Corp. 'The rich are getting richer, and the rich want what they want. They want beachfront and they are prepared to pay a premium for it when it does become available.' Mr Kakavas said the buyer particularly valued the corner position of the 405 sqm lot with 10m waterfrontage offering direct access to the sand and stunning ocean views. Highlights of the mansion's four-level floorplan include open-plan living spaces leading out to an al fresco deck, an internal lift, luxurious master bedroom and ensuite with a freestanding tub overlooking the beach, sauna and steam room, library and home theatre with bar. There's also a temperature-controlled wine cellar, gym and basement garage, as well as an impressive kitchen fitted out with Miele appliances, stone island bench, and a large butler's pantry. 'Meticulously rejuvenated, every aspect of the property exudes luxury, with premium finishes such as travertine, marble, Onyx, and Venetian plaster,' the listing stated. 'The design seamlessly marries natural beauty with modern functionality, offering spaces crafted for lavish entertaining and tranquil relaxation.' Mr Wagner has been steadily building up his property portfolio in recent years, with records showing he bought a property with ocean views in Surfers Paradise in 2022 for $4.6m, and a Brisbane CBD unit in 2023 for $3m.
AU Financial Review
12 hours ago
- AU Financial Review
Lifestyle Communities' exit fees ruled invalid in win for residents
A Victorian tribunal has ruled that ASX-listed housing provider Lifestyle Communities has been charging some of its residents significant exit fees without properly disclosing them and they must be scrapped. Although the Victorian Civil and Administrative Tribunal is yet to issue orders, president Justice Edward Woodward found the controversial exit fees, known as deferred management fees, were 'void' and Lifestyle must not require payment of them.
